Hiring in life sciences? Share your open positions with our professional community. Read more Close

Advertisement

A Dual GSH/ROS-Functional NIR Fluorescent Platform for Synergistic Photodynamic Therapy and Radiosensitization in Nasopharyngeal Carcinoma.

Created on 17 Aug 2026

Authors

Fan Zheng, Yan Mo, Jin Zhou, Chengmin Li, Min Lin, Yingqi Zhao, Jingmei Zhou, Hui Zou, Zhikang Chen, Runsha Xiao, Xueping Feng, Wenbin Zeng

Published in

Small (Weinheim an der Bergstrasse, Germany). Pages e74401. Aug 17, 2026. Epub Aug 17, 2026.

Abstract

High-precision tumor theranostic systems capable of real time monitoring are imperatively required for optimizing the spatial targeting accuracy during radiotherapy and surgical resection across clinical management of nasopharyngeal carcinoma (NPC). However, the clinical application of photodynamic therapy (PDT) is impeded by the suboptimal reactive oxygen species (ROS) generation efficiency and inadequate visualization of redox procedure. In this study, we developed a theranostic platform HSF, featuring integrated tumor-specific near-infrared (NIR) fluorescence imaging and photodynamic ROS generation for real time monitoring and targeted radiotherapy of solid malignancies for NPC. Mechanistically, HSF was initially activated by the elevated glutathione (GSH) levels in the tumor microenvironment, which concomitantly turned on its NIR fluorescence and photodynamic properties. The resulting NIR fluorescence allowed for tumor visualization, while the PDT-triggered oxidative stress further consumed intracellular GSH, thereby ultimately inducing ferroptosis. In NPC cell-derived xenograft models, HSF demonstrated exceptional biocompatibility and effective in vivo retention. This multifunctional photosensitizer enabled precise radiotherapy navigation via real time fluorescent monitoring and ferroptosis-mediated therapeutic mechanisms, offering a transformative approach for real time visualization-guided NPC therapy.

PMID:
42605989
Bibliographic data and abstract were imported from PubMed on 17 Aug 2026.

Read full publication at:
Please sign in to see all details.

Advertisement

Stats

  • Community rating n/a 0 votes
  • Reviewers' rating n/a 0 votes
  • Your rating

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

  • Recommendations n/a n/a positive of 0 vote(s)
  • Views 10
  • Comments 0

Recommended by

  • No recommendations yet.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.

Advertisement